Tectonic Therapeutic Inc TECX 深 滬
等待開盤 02-10 09:30:00 美东时间
24.83
+0.460
+1.89%
華盛通- 最 高25.00
- 今 開24.42
- 成交量 26.67万股
- 最 低 23.67
- 昨 收 24.37
- 總市值 4.65亿
- 52周最高 35.44
- 市盈率 靜 --
- 換手率 1.43%
- 52周最低 13.70
- 委 比 -13.42%
- 總股本 1871.63万
- 歷史最高 644.40
- 量 比 0.58
- 振 幅 5.46%
- 歷史最低 6.72
- 每 手 1
- 風險率 3.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Truist Securities Maintains Buy on Tectonic Therapeutic, Lowers Price Target to $60
Truist Securities analyst Danielle Brill maintains Tectonic Therapeutic (NASDAQ:TECX) with a Buy and lowers the price target from $64 to $60.
01-09 01:23
Tectonic Therapeutic Q3 EPS $(1.02) Beats $(1.05) Estimate
Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.05) by 2.86 percent. This is a 15 percent increase over losses of $(1.20) per share from
2025-11-07 06:07
Tectonic Therapeutic shares are trading higher after the company announced topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45 in patients with Group 2 PH‑HFrEF.
Tectonic Therapeutic shares are trading higher after the company announced topl...
2025-10-30 04:37
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
Tectonic Therapeutic announced positive results from its Phase 1b Part B trial of TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF). TX45 demonstrated significant improvements in left heart function and pulmonary hemodynamics, including reductions in PCWP and PVR, and increases in cardiac output. The treatment was well-tolerated with no serious...
2025-10-29 20:01
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
2025-09-04 09:49
Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
2025-09-02 20:00
Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic Therapeutic, a clinical-stage biotech company focused on therapeutic proteins and antibodies targeting GPCRs, announced that its management will participate in three investor conferences in September 2025. The events include the 2025 Wells Fargo Healthcare Conference in Boston on September 3, the Cantor Global Healthcare Conference in New York on September 4 featuring CFO Daniel Lochner and CBO Marc Schwabish, and the Morgan Stanley 23rd...
2025-08-28 13:00
Tectonic Therapeutic shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Tectonic Therapeutic shares are trading lower after the company reported worse-...
2025-08-08 04:58
Tectonic Therapeutic joins Russell 3000 index
Tectonic Therapeutic (NASDAQ:TECX) has been added to the broad-market Russell 3000 Index as part of the 2025 Russell US Indexes annual reconstitution. The addition is effective after the open of US eq...
2025-06-30 21:21
